SynthesisScientific reports2016
Early clearance of Chikungunya virus in children is associated with a strong innate immune response.
Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Systems analysis of subjects acutely infected with the Chikungunya virus.PLoS pathogens · 2019Trial
- Early Immune Hypoactivation and Persistent Innate Reprogramming Characterize Chronic Chikungunya Disease.bioRxiv : the preprint server for biology · 2026Article
- Chikungunya virus in dengue-suspected patients: Molecular evidence from the 2019 outbreak in Yangon, Myanmar.PLoS neglected tropical diseases · 2026Article
- Emerging local chikungunya virus transmission in a major urban area in Southern China: characteristics of clinical manifestations, viral evolution and climatic influences.National science review · 2026Article
- Immune features and clinical characteristics of chikungunya fever in children: differences from adults and across pediatric age groups.Frontiers in pediatrics · 2026Review
- Longitudinal analysis of post-acute chikungunya-associated arthralgia in children and adults: A prospective cohort study in Managua, Nicaragua (2014-2018).PLoS neglected tropical diseases · 2024Article
- Unraveling the complex interplay: immunopathology and immune evasion strategies of alphaviruses with emphasis on neurological implications.Frontiers in cellular and infection microbiology · 2024Review
- Study of kaempferol in the treatment of COVID-19 combined with Chikungunya co-infection by network pharmacology and molecular docking technology.Informatics in medicine unlocked · 2023Article
- Chikungunya patient transcriptional signatures faithfully recapitulated in a C57BL/6J mouse model.Frontiers in immunology · 2022Article
- Evidence of Chikungunya virus seroprevalence in Myanmar among dengue-suspected patients and healthy volunteers in 2013, 2015, and 2018.PLoS neglected tropical diseases · 2021Article
- Single-cell analysis of arthritogenic alphavirus-infected human synovial fibroblasts links low abundance of viral RNA to induction of innate immunity and arthralgia-associated gene expression.Emerging microbes & infections · 2021Article
- Clinical Features of Acute Chikungunya Virus Infection in Children and Adults during an Outbreak in the Maldives.The American journal of tropical medicine and hygiene · 2021Article
- Overview on Chikungunya Virus Infection: From Epidemiology to State-of-the-Art Experimental Models.Frontiers in microbiology · 2021Review
- Acute-Phase Levels of CXCL8 as Risk Factor for Chronic Arthralgia Following Chikungunya Virus Infection.Frontiers in immunology · 2021Article
- Oral lesions are frequent in patients with Chikungunya infection.Journal of travel medicine · 2020Article
- A clinical scoring system to predict long-term arthralgia in Chikungunya disease: A cohort study.PLoS neglected tropical diseases · 2020Article
- Immunological Evaluation for Personalized Interventions in Children with Tuberculosis: Should It Be Routinely Performed?Journal of immunology research · 2020Article
- Rheumatic manifestations of chikungunya: emerging concepts and interventions.Nature reviews. Rheumatology · 2019Review
- Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate.EMBO molecular medicine · 2019Article
- Children with open tibial fractures show significantly lower infection rates than adults: clinical comparative study.International orthopaedics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya fever (CHIKF) is a global infectious disease which can affect a wide range of age groups. The pathological and immunological response upon Chikungunya virus (CHIKV) infection have been reported over the last few years. However, the clinical profile and immune response upon CHIKV infection in children remain largely unknown. In this study, we analyzed the clinical and immunological response, focusing on the cytokine/chemokine profile in a CHIKV-infected pediatric cohort from Sarawak, Malaysia. Unique immune mediators triggered upon CHIKV infection were identified through meta-analysis of the immune signatures between this pediatric group and cohorts from previous outbreaks. The data generated from this study revealed that a broad spectrum of cytokines/chemokines is up-regulated in a sub-group of virus-infected children stratified according to their viremic status during hospitalization. Furthermore, different immune mediator profiles (the levels of pro-inflammatory cytokines, chemokines and growth and other factors) were observed between children and adults. This study gives an important insight to understand the immune response of CHIKV infection in children and would aid in the development of better prognostics and clinical management for children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.